Harry Jr. Thomasian Acquires 8,284 Shares of Precigen (NASDAQ:PGEN) Stock

Key Points

• Harry Jr. Thomasian, CFO of Precigen, acquired a total of 11,216 shares of the company's stock in two transactions, increasing his ownership by 1.81% and bringing his total holdings to approximately $1.69 million.
• Precigen's shares recently saw a slight increase in trading, reaching $3.51, with a market cap of $1.05 billion and a price-to-earnings ratio of -8.36.
• Equities analysts have shown optimism by revising Precigen's ratings, with several upgrading their price targets to a consensus target price of $8.25, indicating a potential for significant growth.

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) CFO Harry Jr. Thomasian acquired 8,284 shares of the firm's stock in a transaction dated Thursday, September 25th. The shares were purchased at an average price of $3.62 per share, for a total transaction of $29,988.08. Following the completion of the transaction, the chief financial officer directly owned 465,694 shares in the company, valued at approximately $1,685,812.28. This trade represents a 1.81% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Harry Jr. Thomasian also recently made the following trade(s):

• On Friday, September 26th, Harry Jr. Thomasian acquired 2,932 shares of Precigen stock. The shares were purchased at an average price of $3.42 per share, for a total transaction of $10,027.44.

Precigen Price Performance

Shares of PGEN stock traded up $0.03 on Friday, hitting $3.51. 4,337,538 shares of the stock traded hands, compared to its average volume of 4,133,891. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -8.36 and a beta of 1.82. Precigen, Inc. has a 52 week low of $0.65 and a 52 week high of $5.22. The firm has a 50 day simple moving average of $3.07 and a two-hundred day simple moving average of $2.05.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03. The firm had revenue of $0.86 million for the quarter, compared to the consensus estimate of $0.67 million. Precigen had a negative net margin of 2,868.66% and a negative return on equity of 842.83%. Sell-side analysts forecast that Precigen, Inc. will post -0.32 EPS for the current year.

Institutional Trading of Precigen

A number of hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers boosted its holdings in Precigen by 3.7% during the second quarter. Rhumbline Advisers now owns 198,078 shares of the biotechnology company's stock worth $281,000 after buying an additional 7,041 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Precigen by 12.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company's stock worth $122,000 after buying an additional 9,043 shares in the last quarter. ProShare Advisors LLC boosted its holdings in Precigen by 26.6% during the fourth quarter. ProShare Advisors LLC now owns 51,822 shares of the biotechnology company's stock worth $58,000 after buying an additional 10,900 shares in the last quarter. Invesco Ltd. boosted its holdings in Precigen by 43.7% during the second quarter. Invesco Ltd. now owns 62,955 shares of the biotechnology company's stock worth $89,000 after buying an additional 19,149 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in Precigen by 11.6% during the fourth quarter. Bank of America Corp DE now owns 207,300 shares of the biotechnology company's stock worth $232,000 after buying an additional 21,626 shares in the last quarter. 33.51% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. JPMorgan Chase & Co. raised shares of Precigen from an "underweight" rating to a "neutral" rating in a research note on Friday, August 15th. JMP Securities boosted their price target on shares of Precigen from $6.00 to $8.00 and gave the company a "market outperform" rating in a report on Tuesday, August 19th. HC Wainwright reissued a "buy" rating and set a $8.50 target price on shares of Precigen in a research report on Tuesday, August 19th. Citigroup restated an "outperform" rating on shares of Precigen in a research note on Tuesday, August 19th. Finally, Wall Street Zen upgraded shares of Precigen from a "sell" rating to a "hold" rating in a research note on Saturday, July 12th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, Precigen has an average rating of "Moderate Buy" and a consensus target price of $8.25.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.